Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brimonidine - Allergan

Drug Profile

Brimonidine - Allergan

Alternative Names: AGN 190342; AGN 190342LF; Aiphagan Ophthalmic Solution 0.1%; Alphagan; Alphagan P; Alphagan Z; Brimonidine tartrate; DE 087; SNJ-2022; UK 1430 18; UK 14304

Latest Information Update: 05 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Allergan; Senju Pharmaceutical
  • Class Antiglaucomas; Antihypertensives; Imidazoles; Quinoxalines; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension
  • Phase II Dry age-related macular degeneration
  • No development reported Retinal detachment; Retinitis pigmentosa
  • Discontinued Neurological disorders

Most Recent Events

  • 30 Oct 2018 Efficacy data from the phase II BEACON trial in Dry age-related macular degeneration released by Allergan
  • 30 Oct 2018 Allergan plans a phase III trial for brimonidine intravitreal implant in geographic atrophy due to age-related macular degeneration, in the second half of 2019
  • 31 Aug 2018 Brimonidine terminates phase II trials in Dry age-related macular degeneration in USA, Australia, France, Germany, Italy and United Kingdom (Intravitreous) (NCT02087085)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top